Biocryst Pharmaceuticals Inc Stock Price, News & Analysis

BioCryst Pharmaceuticals (Nasdaq: BCRX) reported new findings from the APeX-S clinical trial on ORLADEYO (berotralstat), showcasing sustained attack-free days for patients over 96 weeks. Presented at the C1-inhibitor Deficiency & Angioedema Workshop in Budapest, the trial demonstrated a reduction in hereditary angioedema (HAE) attack rates across various demographics, including age and gender. This oral medication is designed for patients aged 12 and older, and the results affirm its safety and effectiveness, with mild adverse events reported. Patients aged 12-17 maintained an attack-free status 97% of the time, while older patients also showed significant improvements in attack reduction rates. The commitment to expand ORLADEYO's accessibility to HAE patients globally remains robust.

BioCryst Pharmaceuticals (BCRX) announced it will report its first quarter 2023 financial results on May 3, 2023. The management will host a conference call and webcast at 8:30 a.m. ET to discuss these results and provide a corporate update. Interested parties can access the live call by dialing the designated numbers or via the company's investor website. BioCryst focuses on developing novel oral medicines for rare diseases, with its product ORLADEYO (berotralstat) approved in the U.S. and several international markets. In addition, the company is advancing programs targeting the complement system, including the clinical development of BCX10013. More details are available on their website.

BioCryst Pharmaceuticals (BCRX) announced a $450 million financing deal from Pharmakon Advisors. The company will initially draw $300 million, expecting to receive around $26 million net proceeds after repaying debts. This new five-year credit facility carries an interest rate of SOFR + 7.00%, with an option to defer cash interest payments for the first six quarters.

With this financing, BioCryst extends its repayment timeline from 2025 to 2028, aligning with anticipated peak revenues of $1 billion for its drug ORLADEYO. The agreement significantly improves financial terms from a previous credit arrangement, reducing reliance on capital markets. Pharmakon Advisors emphasizes its support for BioCryst’s continued growth and commitment to rare disease treatments.

BioCryst Pharmaceuticals (BCRX) announced its participation in several upcoming investor conferences. The company will present at:

• The 22nd Annual Needham Virtual Healthcare Conference on April 19 at 8:45 a.m. ET
• The BofA Securities 2023 Health Care Conference in Las Vegas on May 10 at 6:00 p.m. ET
• The JMP Securities Life Sciences Conference in New York on May 16 at 2:30 p.m. ET
• The RBC Capital Markets Global Healthcare Conference in New York on May 17 at 8:00 a.m. ET

Live audio webcasts and replays will be accessible in the Investors & Media section of BioCryst’s website. Known for developing oral medicines for rare diseases, BioCryst's ORLADEYO (berotralstat) is already approved in the U.S. and other markets.

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced the grant of stock options and restricted stock units (RSUs) to six new employees, totaling 124,300 shares in stock options and 40,350 shares in RSUs, effective March 31, 2023. The stock options, priced at $8.34 per share, align with BioCryst’s closing stock price on the grant date. Vesting occurs in four equal annual installments, contingent on continued employment, with a 10-year term for the options. This action complies with Nasdaq Listing Rule 5635(c)(4) and supports the company's strategy to attract talent in its mission to develop innovative treatments for rare diseases.

BioCryst Pharmaceuticals (Nasdaq: BCRX) has appointed Dr. Nancy Hutson as chair of its board of directors, effective immediately, succeeding Bob Ingram. Dr. Hutson has over 30 years of experience in the pharmaceutical industry, having previously led global R&D at Pfizer. She has been with BioCryst since 2012 and has contributed significantly to various board committees. Under her leadership, the company aims to continue developing innovative therapies for rare diseases, including its approved oral medicine, ORLADEYO (berotralstat), and its ongoing clinical development programs.

BioCryst Pharmaceuticals (BCRX) announced the granting of stock options and restricted stock units (RSUs) to 12 newly-hired employees. The total grants include options for 110,400 shares and RSUs for 51,300 shares, effective February 28, 2023. The options have an exercise price of $8.85, aligning with the company's common stock closing price on the grant date. Vesting occurs in four equal annual installments, contingent upon the employees' continued service. This grant complies with Nasdaq Listing Rule 5635(c)(4) and is part of BioCryst's Inducement Equity Incentive Plan.

BioCryst Pharmaceuticals announced significant findings from the APeX-S and APeX-2 clinical trials for ORLADEYO (berotralstat), an oral medication for hereditary angioedema (HAE). The final results showed a median attack rate of 0.0 attacks per month in 20 of 24 months. This treatment is well-tolerated, with no new safety signals, and demonstrates sustained reductions in attacks and improved quality of life among patients. These findings were presented at the 2023 AAAAI annual meeting. Real-world data further supports the effectiveness of ORLADEYO, highlighting the ongoing need for accessible treatment options.